[Registration Closed] (Webinar)The 89th HGPI Seminar – Treating the “Untreatable” – How the UK is Incentivizing New Antimicrobial Development to Fight the AMR Crisis (October 19, 2020)
Antimicrobials are a foundational pillar of modern medicine. Since the discovery of penicillin in 1928, antimicrobials have been used across the world to save countless lives from infectious diseases and supported the treatment of non-communicable diseases as well.
However, as humanity uses antimicrobials more and more, the microorganisms that cause infectious diseases adapt, and grow resistant to treatment. This naturally occurring process is called “antimicrobial resistance” (AMR). Without serious action to combat the spread of AMR, we could face a situation in which many people once again die from currently treatable diseases.
Already, in Japan, it is estimated that as many as 8,000 people die every year of AMR-related causes, double the amount of people who die annually from traffic accidents.
Looking toward the future, it has been estimated that by 2050, as many as 10 million people could potentially die of AMR-related causes globally every year.
There are many actions that could help to halt to spread of AMR. Among them, it is vital that the world develop new antimicrobials that can help to treat the sick when existing treatments fail. However, due to certain structural problems in the antimicrobials market, no new classes of antimicrobials have been developed since the 1980s. It is expensive and scientifically challenging to develop a new antimicrobial, and when one is successfully developed, it is better for public health that the new treatment not be widely used, in order to prevent the spread of AMR. The pharmaceutical industry is being asked to develop and produce antimicrobials, and then refrain from actively working to sell them. Many companies have exited the antimicrobial market or gone bankrupt in recent years due to the challenges of this market.
Many interventions are needed to address the challenge of AMR, including global collaboration, innovation, and the concerted stewardship of antimicrobials. Among the potentially effective options is the creation of a “pull incentive” that would pay companies for the value of a new antimicrobial, not the volume sold, after the treatment hits the market. Taking the lead on this problem, the UK Government, NICE, and NHS England and NHS Improvement have announced a pilot project toward the creation of such an incentive. In Japan as well, discussion about pull incentives is gaining momentum, including through the meetings of AMR Alliance Japan and its members.
For this 89th HGPI Seminar, we will invite four speakers to explain the UK’s vision for combatting our AMR crisis, why the UK is working for a pull incentive, and why it’s so important that other countries around the world actively participate in initiatives to halt the spread of AMR.
*Simultaneous interpretation will be provided.
■ Date & Time
Monday, October 19, 18:30-20:00(JST)
18:30-18:35 – Welcome and Introduction
Mr Matt McEnany (Senior Manager, Health and Global Policy Institute / AMR Alliance Japan)
18:35-18:50 – Presentation (tentative): The path toward a world safe from AMR, and the role of pull incentives to that end
Professor Dame Sally Davies (UK Special Envoy on Antimicrobial Resistance)
18:55-19:05 – Presentation (tentative): The need for global collaboration on AMR countermeasures
Dr Louise Norton-Smith (Head of Global Antimicrobial Resistance Strategy & Delivery, UK Department of Health & Social Care)
19:10-19:30 – The design and goals of the UK’s pull incentive pilot
Professor Colm Leonard (Consultant Clinical Adviser, Centre for Health Technology Evaluation at NICE)
Dr Nick Crabb (Programme Director, Scientific Affairs at NICE)
19:35 – 19:55 – Q&A
19:55 – 20:00 – Closing Remarks
Dr Kiyoshi Kurokawa (Chairman, Health and Global Policy Institute)
■ Participation Fee
Professor Dame Sally Davies （UK Government Special Envoy on Antimicrobial Resistance）
Dame Sally Davies was appointed by the Prime Minister as the UK Government’s Special Envoy on AMR in 2019. She is also the 40th Master of Trinity College, Cambridge University.
Dame Sally was the Chief Medical Officer for England and Senior Medical Advisor to the UK Government from 2011-2019. She has become a leading figure in global health including serving as a member of the World Health Organisation (WH O) Executive Board 2014-2016 and as co-convener of the United Nations Inter-Agency Co-ordination Group (IACG) on Antimicrobial Resistance (AMR) reporting in 2019.
In the 2020 New Year Honours, Dame Sally became the second woman (and the first outside the Royal family) to be appointed Dame Grand Cross of the Order of the Bath (GCB) for services to public health and research, having received her DBE in 2009.
Dr. Louise Norton-Smith (Heads, Global antimicrobial resistance (AMR) strategy team, UK Department of Health and Social Care’s Global Health Security programme, which sits alongside the Fleming Fund and other UK Aid-funded projects addressing diseases of epidemic potential)
She oversees the office of the UK Special Envoy on AMR (Prof. Dame Sally Davies), the UK’s £50m Global AMR Innovation Fund (GAMRIF) and the UK government’s work on AMR health diplomacy and advocacy. She leads the UK’s negotiations on AMR within multilateral fora, including at the G7, G20 and the UN and supports the coordination of the UK Government’s international action on AMR, a key element of the UK National Action Plan.
Louise is a career civil servant and has been at the Department of Health and Social Care for nine years, working on both domestic and international health policies and in ministerial private office. Prior to this, Louise was based in Paris and worked with Internews Europe, an international NGO specialising in media development and access to high-quality information. She has also worked in Sudan and Uganda in humanitarian response and sexual and reproductive health projects. Louise has master’s degrees in social anthropology and geography from the University of Edinburgh, Scotland and in international development from the University of Paris (Panthéon-Sorbonne), France where she was an Entente Cordiale scholar.
Professor Colm Leonard （Consultant Clinical Adviser/Consultant Thoracic Physician/Honorary Professor of Respiratory Medicine, National Institute of Health and Care Excellence UK & Manchester University NHS Foundation Trust）
Following undergraduate training in Dublin, and post-graduate experience in Dublin, London and Stanford University in California, Professor Leonard was appointed as a Consultant Thoracic Physician in Manchester in October 2000, and is also an Honorary Professor of Respiratory Medicine at Manchester Academic Health Sciences Centre.
Since 2008 Prof Leonard has also been working as Consultant Clinical Adviser for the Centre for Health Technology Evaluation at NICE which involves assessing which novel pharmaceutical and MedTech products will benefit from a NICE assessment.
A significant amount of Prof Leonard’s time over the past 4 years has been spent with colleagues in NICE, Department of Health and Social Care, and NHS England & Improvement working as clinical lead for the UK project to develop a novel value assessment & reimbursement mechanism for new antimicrobials. Prof Leonard still spends 50% of his time as a pulmonologist specialising in severe lung disease, particularly Sarcoidosis and other interstitial lung problems.
Dr. Nick Crabb （Programme Director – Scientific Affairs, National Institute for Health and Care Excellence (NICE)）
Nick had a 20 year career in analytical science, process technology and general management in the chemical, pharmaceutical and contract laboratory industries prior to joining NICE in 2010 as the associate director responsible for establishing and managing the Diagnostics Assessment Programme. In 2014 Nick was appointed to his current role where he oversees NICE Scientific Advice, the Science Policy and Research programme and NICE’s input to the European Network for Health Technology Assessment (EUnetHTA). Nick has broad scientific and policy interests relating to the evaluation of technologies and interventions to support the development of clinical, public health and social care guidance. His experience includes consideration of HTA issues arising from the availability of novel new products such as cell and gene therapies and work on methods issues relating to the evaluation of antimicrobials. Nick was also the co-chair of the evaluation and commissioning subgroup of the UK regenerative medicine expert group and led NICE’s contribution to a project on the assessment and appraisal of regenerative medicines that reported in 2016.
Registration will close on Thursday, October 15, 2020. Participants will be selected by a draw of lots and informed of the results by Thursday, October 15. Individual supporting members of HGPI will be notified earlier.
After registration has been completed, a confirmation email will be automatically sent. If you do not receive a confirmation email, please contact HGPI by email at email@example.com or by phone at 03-4243-7156.
In the event that you would like to cancel your registration, please inform us by noon on Friday, October 16.